Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals has announced the cessation of 8,415,000 listed options (RCEAN) that expired unexercised on 22 February 2026, each carrying an exercise price of A$1.56. The expiration of these options slightly simplifies the company’s capital structure by removing a block of potential dilution for existing shareholders, but does not directly affect current operations or signal any change in strategic direction.
The notification, lodged as an Appendix 3H on 24 February 2026, formally updates the company’s issued capital on the ASX register. Stakeholders now have greater clarity over the outstanding securities on issue, which may marginally improve transparency and could influence how investors assess Recce’s future capital-raising flexibility and potential share overhang.
The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is an Australia-listed biotechnology company trading under the ASX code RCE. It operates in the pharmaceuticals industry, focusing on the development of therapeutic products, although this specific notice relates solely to its capital structure and does not detail its drug portfolio or market focus.
Average Trading Volume: 138,062
Technical Sentiment Signal: Buy
Current Market Cap: A$169.2M
See more data about RCE stock on TipRanks’ Stock Analysis page.